Rapid and effective evaluation of cancer treatments

Biovica

Biovica is a biotechnology company whose patented technology platform, DiviTum, measures the cell growth rate of patients with solid cancer tumours. The test is designed to provide a measure of how fast cancer grows, as well as whether targeted cancer treatment is effective. Biovica has initially chosen to focus on evaluating the treatment effect on metastatic breast cancer. The company is in an early commercial phase and currently has sales to the research market. Commercial launch in 2020 is estimated for Europe and the United States.

Financials

BIOVICA

SEKm 2017 2018 2019
Sales 3 3 14
Sales growth (%) 330,9 -8,2 470
EBITDA -15 -16 -14
EBITDA margin (%) -558,9 -644 -94,9
EBIT adj -18 -19 -18
EBIT adj margin (%) -659,4 -776 -126,5
Pretax profit -18 -19 -18
EPS rep -1,02 -1,1 -1,03
EPS growth (%) -21,3 -7,7 7,1
EPS adj -1,02 -1,1 -1,03
DPS 0 0 0
EV/EBITDA (x) -9 -7,9 -13,1
EV/EBIT adj (x) -7,7 -6,6 -9,9
P/E (x) -11,3 -8,7 -9,4
P/E adj (x) -11,3 -8,7 -9,4
EV/sales (x) 50,5 50,9 12,5
FCF yield (%) -10,9 -14,1 -14,5
Dividend yield (%) 0 0 0
Net IB debt/EBITDA 4,3 2,6 -0,6

Main shareholders

Biovica

Main shareholders Share capital % Voting shares % Verified
Anders Rylander 22.3 % 33.4 % 30 Sep 2018
Gunnar Rylander 5.6 % 8.6 % 30 Sep 2018
Kristina Gronowitz 2.3 % 3.7 % 30 Sep 2018
Mats Danielsson 1.7 % 2.2 % 31 Dec 2017
Avanza Pension 4.0 % 2.1 % 30 Sep 2018
LYM Consulting AB 2.8 % 1.5 % 30 Sep 2018
Ålandsbanken Fonder 2.4 % 1.3 % 30 Sep 2018
Nordnet Pensionsförsäkring 2.3 % 1.2 % 30 Sep 2018
Per Stålhandske 1.7 % 0.9 % 30 Sep 2018
Lars Holmqvist 1.6 % 0.8 % 30 Sep 2018

Insider list

Biovica

Name
Karin Mattsson
Pontus Nobréus
Wing-Shing Cheng
Wing-Shing Cheng
Wing-Shing Cheng
Pontus Nobréus
Adam Germunder
Arinvest AB
Mattias Bergqvist
Mattias Bergqvist
Show More